| scholarly article | Q13442814 |
| P50 | author | Patrick Maisonneuve | Q37830753 |
| Marco Colleoni | Q56850279 | ||
| P2093 | author name string | G Viale | |
| A Goldhirsch | |||
| A Rocca | |||
| L Orlando | |||
| M T Sandri | |||
| R Ghisini | |||
| G Sanna | |||
| F Nolè | |||
| G Peruzzotti | |||
| L Zorzino | |||
| P433 | issue | 2 | |
| P921 | main subject | thalidomide | Q203174 |
| methotrexate | Q422232 | ||
| metastatic breast cancer | Q12859063 | ||
| P304 | page(s) | 232-238 | |
| P577 | publication date | 2005-12-01 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects | |
| P478 | volume | 17 |
| Q36615612 | A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. |
| Q35836463 | A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas |
| Q54349347 | A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer. |
| Q38249998 | A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials. |
| Q43158828 | Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). |
| Q57787312 | Adjuvant Thalidomide and Metronomic Chemotherapy for the Treatment of Canine Malignant Mammary Gland Neoplasms |
| Q37633173 | Adjuvant chemotherapy--the dark side of clinical trials. Have we learnt more? |
| Q56775297 | An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study |
| Q26822432 | Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials |
| Q37528441 | Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives. |
| Q83940496 | Antitumoral and antimetastatic effects of metronomic chemotherapy with cyclophosphamide combined with celecoxib on murine mammary adenocarcinomas |
| Q53069927 | Apoptosis induction of cardiomyocytes and subsequent fibrosis after irradiation and neoadjuvant chemotherapy. |
| Q34095977 | Breast Cancer Systemic Therapy: The Need for More Economically Sustainable Scientific Strategies in the World |
| Q36465291 | Breast tumour angiogenesis |
| Q35848919 | Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy |
| Q38560651 | Clinical overview of metronomic chemotherapy in breast cancer. |
| Q35918752 | Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers |
| Q41830446 | Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment |
| Q35034703 | Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer |
| Q38788234 | Current achievements and future perspectives of metronomic chemotherapy |
| Q26751245 | Dose-Dense Chemotherapy in Metastatic Breast Cancer: Shortening the Time Interval for a Better Therapeutic Index |
| Q38749215 | Eco-evolution of cancer resistance |
| Q41742917 | Effects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis. |
| Q39516898 | Enhanced antitumor activity of low-dose continuous administration schedules of topotecan in prostate cancer. |
| Q57495758 | Explorative Analysis of Low-Dose Metronomic Chemotherapy with Cyclophosphamide and Methotrexate in a Cohort of Metastatic Breast Cancer Patients |
| Q34537146 | Factors responsible for long-term survival in metastatic breast cancer |
| Q36953443 | Indication of metronomic chemotherapy for metastatic breast cancer: Clinical outcomes and responsive subtypes |
| Q33485606 | Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice |
| Q35988038 | Intravital imaging of the effects of 5-fluorouracil on the murine liver microenvironment using 2-photon laser scanning microscopy |
| Q38659074 | Lack of efficacy of combined antiangiogenic therapies in xenografted human melanoma |
| Q36057458 | Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. |
| Q36359098 | Low-dose "metronomic chemotherapy" with oral cyclophosphamide and methotrexate in metastatic breast cancer: a case report of extraordinarily prolonged clinical benefit. |
| Q37435219 | Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models |
| Q38782118 | Maintenance hormonal and chemotherapy treatment in metastatic breast cancer: a systematic review. |
| Q37338245 | Maintenance treatment in metastatic breast cancer. |
| Q36922920 | Mechanisms of disease: angiogenesis and the management of breast cancer |
| Q33794896 | Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care |
| Q53223630 | Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response. |
| Q26745462 | Metronomic Chemotherapy for Metastatic Breast Cancer – a Systematic Review of the Literature |
| Q37709874 | Metronomic Chemotherapy for Primary Non-Metastatic Breast Cancer - a Systematic Review of the Literature |
| Q64071354 | Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience |
| Q38248269 | Metronomic chemotherapy |
| Q38087885 | Metronomic chemotherapy for cancer treatment: a decade of clinical studies |
| Q37641082 | Metronomic chemotherapy for metastatic breast cancer to prolong time to treatment failure to 12 months or more |
| Q35636032 | Metronomic chemotherapy in anaplastic thyroid carcinoma: a potentially feasible alternative to therapeutic nihilism |
| Q35653510 | Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2- locally advanced breast cancer |
| Q27023579 | Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance |
| Q37158779 | Metronomic chemotherapy: changing the paradigm that more is better |
| Q37763502 | Metronomic chemotherapy: new rationale for new directions |
| Q37236004 | Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma |
| Q54389588 | Metronomic docetaxel chemotherapy inhibits angiogenesis and tumor growth in a gastric cancer model. |
| Q39695611 | Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma |
| Q86328955 | Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer |
| Q26830493 | Metronomic therapy for gynecologic cancers |
| Q39804633 | Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World? |
| Q38322346 | Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue? |
| Q47347568 | Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report. |
| Q50056556 | Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group |
| Q91100206 | Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer |
| Q34403657 | Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles |
| Q36791086 | Primary extraosseous Ewing sarcoma of the lung in children |
| Q57541220 | Prospective trial of metronomic chlorambucil chemotherapy in dogs with naturally occurring cancer |
| Q35251489 | Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer |
| Q30986337 | Rapid induction of orthotopic hepatocellular carcinoma in immune-competent rats by non-invasive ultrasound-guided cells implantation |
| Q40448516 | Resistance to metronomic chemotherapy and ways to overcome it. |
| Q38916996 | Response assessment in metronomic chemotherapy: RECIST or PERCIST? |
| Q43566642 | Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients. |
| Q39455513 | Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients |
| Q56779471 | Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy |
| Q36309028 | The efficacy and toxicity profile of metronomic chemotherapy for metastatic breast cancer: A meta-analysis |
| Q42573450 | The emerging low-dose therapy for advanced cancers |
| Q36621435 | The multifaceted circulating endothelial cell in cancer: towards marker and target identification. |
| Q33257718 | Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer |
| Q38046584 | Triple-negative breast cancer in the older population |
| Q47149222 | Whether low-dose metronomic oral cyclophosphamide improves the response to docetaxel in first-line treatment of non-triple-negative metastatic breast cancer |
Search more.